CHRN is a weak-quality, momentum-failing name with no clear engine edge; the risk case dominates and the position is flagged for exit rather than accumulation.
Thesis pillars
- Quality Below Floor→Stable
- Momentum Gate Failure→Stable
- No Clear Engine Edge→Stable
- +1 more pillar — see the Why tab for full reasoning
ChronoScale Corporation (CHRN) Stock Analysis
Range Bound setup
Technology · Information Technology Services
Sell if holding. Engine safety override at $17.89: Quality below floor (0.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 3.7/10. Specifically: Below-average business quality; Rich valuation; Negative price momentum.
ChronoScale Corporation (formerly Ekso Bionics Holdings) was, per this 10-K, a maker of wearable robotic exoskeletons — EksoNR, Ekso Indego Therapy, and Ekso Indego Personal — for rehabilitation and mobility in spinal cord injury and stroke patients. On May 5, 2026, it completed... Read more
Sell if holding. Engine safety override at $17.89: Quality below floor (0.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 3.7/10. Specifically: Below-average business quality; Rich valuation; Negative price momentum. Chart setup: RSI 50 mid-range, Bollinger mid-band. Score 3.7/10, moderate confidence.
Passes 5/8 gates (clean insider activity, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and 8k serious 2.05. Suitability: aggressive.
About ChronoScale Corporation
About ChronoScale Corporation
ChronoScale Corporation, until May 2026 named Ekso Bionics Holdings, designed and sold wearable robotic exoskeletons — EksoNR, Ekso Indego Therapy, and Ekso Indego Personal — cleared by the FDA for spinal cord injury, stroke, and multiple sclerosis patients. On May 5, 2026, the company completed a reverse-merger Business Combination with Applied Digital Corporation's cloud computing subsidiary, with Applied Digital affiliates receiving shares representing approximately 97% of the combined company. On May 29, 2026, the Board committed to divesting the legacy Ekso exoskeleton business to focus solely on cloud computing.
As described in the 10-K, the legacy Ekso business earned revenue primarily from Enterprise Health sales — capital purchases or third-party-financed subscriptions of EksoNR and Ekso Indego Therapy devices to rehabilitation hospitals and integrated delivery networks — with sales cycles of eight to twelve months, plus Personal Health sales of the Ekso Indego Personal device to individuals, reimbursed by Medicare at approximately $91,000 per device following an April 2024 CMS payment determination. Distribution ran through a direct salesforce in the Americas and a mix of direct and distributor channels in EMEA and APAC, with veterans served through Service-Disabled Veteran-Owned Small Business distributors under a Department of Veterans Affairs program. None of this legacy operating structure describes ChronoScale going forward: the Applied Digital Cloud business the company acquired on May 5, 2026 is a cloud computing operation, and the Board's May 29, 2026 decision to divest Ekso Bionics — expected to incur material severance, lease-termination, and transaction charges not yet estimated — means the exoskeleton products, reimbursement dynamics, and distribution channels described above will not be part of ChronoScale's ongoing business once the divestiture completes.
Show full overview
ChronoScale's post-merger capital structure concentrates control with a single counterparty: Applied Digital Corporation's affiliates received shares expected to represent approximately 97% of the combined company's outstanding equity in exchange for contributing 100% of Applied Digital Cloud's stock, leaving pre-merger Ekso Bionics shareholders with a small minority stake in a company now steered entirely by Applied Digital's cloud strategy. Because the Board voted within weeks of closing to shed the entire pre-merger business, any investor evaluating ChronoScale based on the exoskeleton products, FDA clearances, or Medicare reimbursement dynamics described in this 10-K would be assessing a business the company itself has already decided to exit.
See also: Technology · Information Technology Services
From ChronoScale Corporation's most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-06Recent Developments — ChronoScale Corporation
Latest news
- NEWS Terawulf, Ceva, Western Digital And Other Big Stocks Moving Higher On Monday — benzinga Jul 6, 2026 neutral
- NEWS 12 Information Technology Stocks Moving In Wednesday's Intraday Session — benzinga Jul 1, 2026 neutral
- NEWS ChronoScale Files Prospectus Related To Resale Of 1.1M Common Shares By Selling Stockholders — benzinga Jun 30, 2026 negative
Generated 2026-07-06T20:41:43Z.
Thesis
Key Metrics
Quality Signals
Material Events(8-K, last 90d)
- 2026-05-05Item 5.01HIGHEkso Bionics Holdings, Inc. completed its Business Combination with Applied Digital Corporation's cloud computing subsidiary under a February 15, 2026 Contribution and Exchange Agreement, changing its name to ChronoScale Corporation. Applied Digital affiliates received newly issued shares expected to represent approximately 97% of the combined company's outstanding equity.SEC filing →
- 2026-06-04Item 2.05MEDIUMOn May 29, 2026, ChronoScale's Board committed to divesting its wholly owned subsidiary Ekso Bionics, Inc. (the legacy exoskeleton business) to focus operations solely on the newly acquired cloud business, expecting completion the following fiscal quarter. The Company had not yet estimated total exit costs, including severance, lease-termination, and transaction expenses.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Unprofitable operations — net margin -86.2%. Quality floor flags this regardless of sector context.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $17.89: Quality below floor (0.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 3.7/10. Specifically: Below-average business quality; Rich valuation; Negative price momentum. Chart setup: RSI 50 mid-range, Bollinger mid-band. Prior stop was $16.97. Score 3.7/10, moderate confidence.
Take-profit target: $27.64 (+51.5% upside). Prior stop was $16.97. Stop-loss: $16.97.
Quality below floor (0.8 < 4.0).
ChronoScale Corporation trades at a P/E of N/A (forward N/A). TrendMatrix value score: 3.2/10. Verdict: Sell.
8 analysts cover CHRN with a consensus score of 4.0/5.
What does ChronoScale Corporation do?ChronoScale Corporation (formerly Ekso Bionics Holdings) was, per this 10-K, a maker of wearable robotic exoskeletons —...
ChronoScale Corporation (formerly Ekso Bionics Holdings) was, per this 10-K, a maker of wearable robotic exoskeletons — EksoNR, Ekso Indego Therapy, and Ekso Indego Personal — for rehabilitation and mobility in spinal cord injury and stroke patients. On May 5, 2026, it completed a reverse merger with Applied Digital Corporation's cloud computing subsidiary, with Applied Digital affiliates receiving shares representing approximately 97% of the combined company; on May 29, 2026, the Board committed to divesting the legacy Ekso business to focus solely on cloud computing.